Top

Published in:

01-02-2014 | Original Paper

B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—The Heinz Nixdorf Recall Study

Authors: Kaffer Kara, Amir A. Mahabadi, Marie H. Geisel, Nils Lehmann, Hagen Kälsch, Marcus Bauer, Till Neumann, Nico Dragano, Susanne Moebus, Stefan Möhlenkamp, Karl-Heinz Jöckel, Raimund Erbel

Published in: Clinical Research in Cardiology | Issue 2/2014

Abstract

Background

A B-type natriuretic peptide (BNP) threshold of 100 pg/ml is used in practice for identification of heart failure, but data about the “normal” distribution of BNP in a large population in primary prevention are rare. We aimed to characterize the BNP distribution in a healthy subset of a population-based cohort and to evaluate the association of elevated BNP levels with major events.

Methods

In a first step, we determined gender-specific distribution and 90th percentiles of BNP in participants who were at baseline free from known determinants of increased BNP, i.e. cardiovascular disease, hypertension or chronic kidney disease. Consecutively, the association of BNP levels above these 90th percentiles with subsequent cardiovascular and coronary events was assessed in the entire cohort.

Results

In the BNP-normal sub-sample (n = 1,639), we defined gender-specific 90th percentile of BNP (31.3 pg/ml for men, 45.5 pg/ml for women). From overall 3,697 subjects (mean age 59.4, 52.4 % female), 194 subjects developed a major cardiovascular event and 122 myocardial infarction during a mean follow-up period of 8.0 ± 1.5 years. The 90th percentiles derived from the normal subset as threshold showed strong associations with major events in the entire cohort even after adjusting for traditional risk factors: hazard ratio (95 % CI): 1.86 (1.37; 2.53), p < 0.0001 for cardiovascular, and 1.77 (1.19; 2.62), p = 0.005 for coronary events.

Conclusion

The gender-specific 90th percentile of BNP (31 pg/ml for males and 45 pg/ml for females) obtained from a BNP-normal sub-sample is associated with incident major cardiovascular and coronary events, suggesting that even BNP values lower than 100 pg/ml could imply prognostic information in the general population.

Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167PubMedCrossRef

Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMedCrossRef

Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954PubMedCrossRef

Böhm M, Voors AA, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973–981PubMedCrossRef

Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB (2003) Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17:1105–1107PubMed

Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y, Yamaguchi M, Hori R, Yasue H, Nakao K (1995) Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92:1558–1564PubMedCrossRef

Struthers A, Lang C (2007) The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’ target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 28:1678–1682PubMedCrossRef

Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD (2012) Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol 60:960–968PubMedCrossRef

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663PubMedCrossRef

10.

Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, Onodera M, Ishibashi Y, Itai K, Onoda T, Ohsawa M, Tanno K, Sakata K, Shinichi O, Ogasawara K, Ogawa A, Kuribayashi T, Okayama A (2011) Sex-specific threshold levels of plasma B-type natriuretic Peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. Am J Cardiol 108:1564–1569PubMedCrossRef

11.

Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177–2187PubMedCrossRef

12.

Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120–127PubMedCrossRef

13.

Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH (2010) Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 55:785–791PubMedCrossRef

14.

Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102:259–268PubMedCrossRef

15.

Nakamura M, Tanaka F, Onoda T, Takahashi T, Sakuma M, Kawamura K, Tanno K, Ohsawa M, Itai K, Sakata K, Makita S, Iwate KENCO Study Groups (2010) Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol 143:124–129PubMedCrossRef

16.

Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745–751PubMedCrossRef

17.

Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Grönemeyer D, Seibel R, Kälsch H, Bröcker-Preuss M, Mann K, Siegrist J, Jöckel KH, Heinz Nixdorf Recall Study Investigative Group (2010) Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: The Heinz Nixdorf Recall study. J Am Coll Cardiol 56:1397–1406PubMedCrossRef

18.

Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel KH, Erbel R (2002) Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf Recall Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 144:212–218PubMedCrossRef

19.

Möhlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, Siegrist J, Mann K, Jöckel KH, Erbel R, Heinz Nixdorf Recall Study Investigators (2011) Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol 57:1455–1464PubMedCrossRef

20.

Schmermund A, Möhlenkamp S, Berenbein S, Pump H, Moebus S, Roggenbuck U, Stang A, Seibel R, Grönemeyer D, Jöckel KH, Erbel R (2006) Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. Atherosclerosis 185:177–182PubMedCrossRef

21.

Stang A, Moebus S, Dragano N, Beck EM, Möhlenkamp S, Schmermund A, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Investigation Group (2005) Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. Eur J Epidemiol 20:489–496PubMedCrossRef

22.

Schmermund A, Lehmann N, Bielak LF, Yu P, Sheedy PF 2nd, Cassidy-Bushrow AE, Turner ST, Moebus S, Möhlenkamp S, Stang A, Mann K, Jöckel KH, Erbel R, Peyser PA (2007) Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. Atherosclerosis 195:207–216CrossRef

23.

Jöckel KH, Lehmann N, Jaeger BR, Moebus S, Möhlenkamp S, Schmermund A, Dragano N, Stang A, Grönemeyer D, Seibel R, Mann K, Volbracht L, Siegrist J, Erbel R (2009) Smoking cessation and subclinical atherosclerosis–results from the Heinz Nixdorf Recall Study. Atherosclerosis 203:221–227PubMedCrossRef

24.

Moebus S, Stang A, Möhlenkamp S, Dragano N, Schmermund A, Slomiany U, Hoffmann B, Bauer M, Broecker-Preuss M, Mann K, Siegrist J, Erbel R, Jöckel KH, Heinz Nixdorf Recall Study Group (2009) Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort–results of the Heinz Nixdorf Recall Study. Diabetologia 52:81–89PubMedCrossRef

25.

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832PubMedCrossRef

26.

Erbel R, Möhlenkamp S, Lehmann N, Schmermund A, Moebus S, Stang A, Grönemeyer D, Seibel R, Mann K, Volbracht L, Dragano N, Siegrist J, Jöckel KH (2008) Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis 197:662–672PubMedCrossRef

27.

Truong QA, Massaro JM, Rogers IS, Mahabadi AA, Kriegel MF, Fox CS, O’Donnell CJ, Hoffmann U (2011) Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study. Circ Cardiovasc Imaging 5:147–154PubMedCentralPubMedCrossRef

28.

Rogers IS, Massaro JM, Truong QA, Mahabadi AA, Kriegel MF, Fox CS, Thanassoulis G, Isselbacher EM, Hoffmann U, O’Donnell CJ (2013) Distribution, determinants, and normal reference values of thoracic and abdominal aortic diameters by computed tomography (from the Framingham Heart Study). Am J Cardiol 111:1510–1516PubMedCrossRef

29.

Thanassoulis G, Massaro JM, Hoffmann U, Mahabadi AA, Vasan RS, O’Donnell CJ, Fox CS (2010) Prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat depots in the Framingham heart study. Circ Cardiovasc Imaging 3:559–566PubMedCentralPubMedCrossRef

30.

Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241CrossRef

31.

Lin D, Wei LJ, Ying Z (1993) Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 80:557–572CrossRef

32.

Kara K, Mahabadi AA, Berg MH, Lehmann N, Möhlenkamp S, Kälsch H, Bauer M, Moebus S, Dragano N, Jöckel KH, Neumann T, Erbel R (2013) Predicting Risk of Coronary Events and All-cause Mortality: Role of B-Type Natriuretic Peptide above Traditional Risk Factors and Coronary Artery Calcium Scoring in the General Population—The Heinz Nixdorf Recall Study. Eur J Prev Cardiol [Epub ahead of print]

Title: B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—The Heinz Nixdorf Recall Study
Authors: Kaffer Kara
Amir A. Mahabadi
Marie H. Geisel
Nils Lehmann
Hagen Kälsch
Marcus Bauer
Till Neumann
Nico Dragano
Susanne Moebus
Stefan Möhlenkamp
Karl-Heinz Jöckel
Raimund Erbel
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 2/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0628-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—The Heinz Nixdorf Recall Study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND

Vascular involvement in cardiac giant cell myocarditis: a new pathophysiological aspect

Can postoperative mean transprosthetic pressure gradient predict survival after aortic valve replacement?

Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold

Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system

Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure